Table 2 Clinical characteristics according to PDGF group
From: Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis
| Â | n | PDGF group | p | ||
|---|---|---|---|---|---|
Absent | Medium | High | |||
38 | 29 | 33 | |||
Diagnosis, CIS | n (%) | 11 (28.9%) | 11 (37.9%) | 9 (27.3%) | 0.625 |
Diagnosis, RR | n (%) | 27 (71.1%) | 18 (62.1%) | 24 (72.7%) | |
Age | Mean (SD) | 33.4 (9.38) | 32.3 (8.98) | 35.2 (11.82) | 0.625a |
Sex, F | n (%) | 29 (76.3%) | 18 (62.1%) | 23 (69.7%) | 0.458 |
Disease duration, months | Median (IQR) | 8 (1.7–18.3) | 7 (1–34) | 12 (3–84) | 0.218b |
Disease activity at diagnosis | |||||
 No activity | n (%) | 16 (42.1%) | 11 (37.9%) | 15 (45.5%) | 0.817 |
 Clinical relapse and/or Gd+ MRI | n (%) | 22 (61.1%) | 18 (62.1%) | 18 (54.5%) | |
Escalation to second line | n (%) | 8 (21.1%) | 7 (24.1%) | 4 (12.1%) | 0.446 |
EDSS at baseline | Median (IQR) | 2 (1–2) | 1.5 (1–2) | 2 (1–2) | 0.998 |